GBDC Stock +24.76% Since The Golden Star Was Identified GBDC Stock +24.76% Since The Golden Star Was Identified Unlock Golden Star List
$13.73
-0.530 (-3.72%)
At Close: Apr 19, 2024
Forecast Earnings Fundamentals Insider Trading Signals Historical Prices Predictions News Profile

Jelmyto And UGN-102 Will Likely Drive Strong Returns For UroGen Shareholders

 02:07pm, Monday, 01'st Mar 2021
UroGen is using its proprietary reverse thermal gel technology to pioneer a line of therapies for upper urinary tract cancers that are substantially better than current options.

URGN Is Worth $50/Share Should It Trade At Revenue Multiples Consistent With Its Peers

 03:00pm, Sunday, 10'th Jan 2021
UroGen's Jelmyto, approved April 2020 for LG-UTUC, has a J code effective 1/1/2021 allowing for dramatically more convenient coding & reimbursement. Revenues should be about $115,000/patient as labell

UroGen Pharma to Present at the Virtual 39th Annual J.P. Morgan Healthcare Conference

 08:00am, Wednesday, 06'th Jan 2021
PRINCETON, N.J.--(BUSINESS WIRE)--UroGen Pharma Ltd. (Nasdaq:URGN), a biopharmaceutical company dedicated to building and commercializing novel solutions that treat specialty cancers and urologic dise

UroGen Pharma Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

 08:00am, Friday, 04'th Dec 2020
PRINCETON, N.J.--(BUSINESS WIRE)--UroGen Pharma Ltd. (Nasdaq: URGN), a biopharmaceutical company dedicated to building and commercializing novel solutions that treat specialty cancers and urologic dis

UroGen Pharma Announces Podium Presentation of Final Jelmyto® Data From Pivotal OLYMPUS Trial at the Annual Meeting of the Society of Urologic Oncology

 08:00am, Thursday, 03'rd Dec 2020
PRINCETON, N.J.--(BUSINESS WIRE)--UroGen Pharma Ltd. (Nasdaq: URGN) a biopharmaceutical company dedicated to building and commercializing novel solutions that treat specialty cancers and urologic dise

UroGen Pharma Announces November 2020 Conference Schedule

 08:00am, Tuesday, 10'th Nov 2020
PRINCETON, N.J.--(BUSINESS WIRE)--UroGen Pharma Ltd. (Nasdaq:URGN), a biopharmaceutical company dedicated to building and commercializing novel solutions that treat specialty cancers and urologic dise

UroGen Pharma's (URGN) CEO Liz Barrett on Q3 2020 Results - Earnings Call Transcript

 03:02pm, Monday, 09'th Nov 2020
UroGen Pharma's (URGN) CEO Liz Barrett on Q3 2020 Results - Earnings Call Transcript

Recap: UroGen Pharma Q3 Earnings

 08:33am, Monday, 09'th Nov 2020
Shares of UroGen Pharma (NASDAQ:URGN) were unchanged after the company reported Q3 results.
Click to get the best stock tips daily for free!

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE